I really don't want to be a doctor

Chapter 172 White Moonlight

"Mr. Jing, tell me." Hammer said, "If there is something I can do to help, it is absolutely obligatory."

"I just want to know, there should be many R&D personnel from China in Pfizer's US R&D headquarters?" Jing Xiaoran said.

"Of course!" Hammer laughed, "Huaxia people are not only smart, but also able to endure hardships and stand hard work. They are very popular in our pharmaceutical industry. We have many senior pharmaceutical engineers at Pfizer."

The R&D department of Pfizer's headquarters brings together cutting-edge talents in the global pharmacology industry, and countless people want to enter here.

Although Huaxia's pharmaceutical industry is not well developed, this is caused by various complicated environments in the country. Huaxia's medical talents are all over the world.R&D talents from China in Pfizer accounted for nearly 10%.

Jing Xiaoran coughed, and said, "Then, there are quite a few Chinese people returning from Pfizer's R&D department every year, right?"

"Mr. Jing, who is this?" Hammer's expression froze slightly, "Poaching?"

Pfizer's scale is large, and personnel turnover must be frequent.

Especially in the relatively boring working environment of the R&D industry, many R&D personnel will choose to earn a fortune abroad. As long as there are suitable jobs in China, they will choose to return to China.

Jing Xiaoran smiled: "Mr. Hammer, I'm not poaching."

"What I mean is that if there are R&D personnel who want to return to work from Pfizer, I welcome them here and provide them with a platform to display their abilities."

Hearing this, Hamer pondered for a moment before saying, "Mr. Jing, after all, this matter involves the flow of our R&D personnel at Pfizer, and the headquarters will definitely not agree to this."

"After all, every research and development personnel is actually a fortune. It is impossible for us to take the initiative to propose such a matter of persuading people to leave in the company."

The backing of every pharmaceutical company is a group of huge R&D talents, which means continuous innovation capabilities; many pharmaceutical companies like to buy semi-finished drugs directly, but such development will be subject to many constraints.

Jing Xiaoran understood what Hamer meant, he just wanted to try to ask.

Coming from Pfizer's "poaching", the quality of such talents must be very high, but it is difficult for Pfizer to release them, and many R&D personnel have signed "non-disclosure agreements."

"However, Mr. Jing, I can use my personal relationship to help you." Hammer changed his subject suddenly.

Jing Xiaoran showed surprise: "Really?"

"Well." Hammer nodded, "I know a research and development personnel from China in the headquarters, and we have a good relationship these years. He once revealed to me that he wanted to return to China, but the medical environment in China is not very good. So he has been hesitant."

"I think I can recommend Mr. Jing's laboratory to him."

"That's really great!" Jing Xiaoran smiled happily.

Hamer can be regarded as one of the top executives in Pfizer, and those who can know Hamer can definitely be regarded as elite talents in the R&D department.

If this matter can be accomplished, for Jing Xiaoran, it will be a blessing in disguise!

He is thinking about where to recruit the first batch of experimenters.

"Mr. Jing, we can be regarded as helping each other, and it's just a matter of effort for me."

Hammer can definitely be regarded as a good person, and he didn't forget to flatter Jing Xiaoran at this time.

In his eyes, Jing Xiaoran is a potential stock worthy of full investment.

Now that Jing Xiaoran has his own experiment again, the future development is limitless, and it is definitely a good deal to have a good relationship with him now.

……

Yang Zhi led Jing Xiaoran to visit around the experiment, and then Hamer and Jing Xiaoran handed over all the equipment and instruments.

From now on, Jing Xiaoran has all the rights to this top laboratory that can be ranked internationally!

The private laboratory is already available, and he can finally make a big splash.

The "white moonlight" in Jing Xiaoran's eyes is the immune checkpoint inhibitor that he has been obsessed with since the beginning.

Immune checkpoint inhibitors, this milestone treatment that has changed the treatment of tumors, has saved the lives of countless cancer patients.

Jing Xiaoran was still holding a review on immune checkpoint inhibitors, which he submitted to The Lancet two years ago, but he did not expect it to be rejected at the time.

He has always remembered this matter, let's see when he can find his way back...

Jing Xiaoran knew the pharmacological mechanism and target of immune checkpoint inhibitors, but did not know the specific molecular formula of the drug, that is to say, no active compound could be found.

There are two difficulties in accomplishing this task.

First, the workload is too heavy for Jing Xiaoran to complete alone.

This requires a research and development team to work together to conduct repeated experiments in permutations and combinations to find active compounds.

What Jing Xiaoran lacks now is people, what he lacks is a large number of "research dogs"!
But even if it is a "research dog", you can't just look for it, you still have to find something that is easy to use. It is best to find a "calf", then his laboratory will really have "combat power".

Second, Jing Xiaoran is now facing another difficulty, that is, he is not clear about the research progress of other pharmaceutical companies on "immune checkpoint inhibitors".

In the past two years, Jing Xiaoran has been following the news about "immune checkpoint inhibitors" worldwide.

Two years ago, a pharmaceutical company was already researching immune checkpoint inhibitors. If Jing Xiaoran wanted to get involved, there would inevitably be competition, which is what is usually called a "scientific research competition"!
Combined with the memory of his previous life, "immune checkpoint inhibitors" will be on the market as soon as a year or two years later.

Once other pharmaceutical companies or experiments develop the drug in advance and successfully pass the Phase 4 clinical trial, it means that their initial investment is all in vain.

It is undoubtedly a "hell" level of difficulty to surpass the research and development progress of other pharmaceutical companies and pass human clinical trials in such a short period of time.

Jing Xiaoran is not sure whether he can catch up with his global medical counterparts and develop "immune checkpoint inhibitors", but since he is reborn, he must try his best.

……

The plaque at the entrance of the laboratory is still blank, just waiting for Jing Xiaoran to name it.

Jing Xiaoran was not very good at naming things, so he simply sought advice from the same-sex dating group in the same city.

Jin Miao: "How is Jinjing Laboratory?"

Zhou Zukun: "Jin Zi, you are really shameless, return the Jinjing Laboratory..."

Lin Xuantong: "Or call it Xiao Ran Pharmacology Laboratory, concise and to the point."

Jin Miao: "No, Xiao Ran is such a low-key person, he definitely wouldn't use this name, how about calling it Huaxia Zhichuang Laboratory?"

Zhou Zukun: "Huaxia Zhichuang...I'll go, you are too low."

Jin Miao: "Kunkun, why do you always hate me?"

……

Hearing everyone's discussion in the group, Jing Xiaoran decided to give up their opinions and think about it slowly.

(End of this chapter)